2014 Fiscal Year Final Research Report
New strategy for drug-resistant cancer cells by targeting long, non-coding/antisense RNA
Project/Area Number |
25640067
|
Research Category |
Grant-in-Aid for Challenging Exploratory Research
|
Allocation Type | Multi-year Fund |
Research Field |
Tumor biology
|
Research Institution | Kochi University |
Principal Investigator |
|
Co-Investigator(Kenkyū-buntansha) |
KONDO Shinji 大学共同利用機関法人情報, システム研究機構(新領域融合研究センター), 特任准教授 (30415161)
KATO Hidemasa 埼玉医科大学, 医学部, 講師 (50292123)
|
Project Period (FY) |
2013-04-01 – 2015-03-31
|
Keywords | 薬剤耐性 / 非コードRNA / エピジェネティクス / トランスクリプトーム / RNA-seq |
Outline of Final Research Achievements |
We established a drug-resistant cell line DTP (non-proliferative immediately after drug treatment), DTEP (cell proliferation resumed), DTEP-r (drug-sensitive after a long culture without drug), starting with PC9 cells, derived from human non-small cell lung cancer, using anticancer drug, gefitinib. We performed RNA-seq (mRNA and total RNA) for each cell line, and identified ncRNA producing gene loci showing unique expression balances between poly(A)+RNA and total RNA. We also obtained differential expression profiles of several genes among cell types, which suggested the phenotypic differences among cell types were due to epigenetic changes.
|
Free Research Field |
分子遺伝学
|